Management of fibrosis: The mesenchymal stromal cells breakthrough

Stem Cells International

Volumn 2014, Issue , 2014, Pages

  Usunier, Benoît ^a   Benderitter, Marc ^a   Tamarat, Radia ^a   Chapel, Alain ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CONNECTIVE TISSUE GROWTH FACTOR; PIRFENIDONE; PROTEIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; APOPTOSIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL INFILTRATION; CELL TRANSFORMATION; CYSTIC FIBROSIS; DRUG EFFICACY; ENDOTHELIAL TO MESENCHYMAL TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; HYPOXIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOGENESIS; PERITONEAL FIBROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION INDUCED FIBROSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; TREATMENT INDICATION; VACCINATION; WOUND HEALING;

EID: 84921260108     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2014/340257     Document Type: Review

References (127)

1. V. Kumar, A. K. Abbas, and N. Fausto, "Tissue renewal and repair: regeneration, healing, and fibrosis," in Pathologic Basis of Disease, V. K. A. K. Abbas and N. Fausto, Eds., Elsevier Saunders, Philadelphia, Pa, USA, 2005.
2. T. A. Wynn, "Cellular and molecular mechanisms of fibrosis," Journal of Pathology, vol. 214, no. 2, pp. 199-210, 2008.
3. A. Chapel, S. Francois, L. Douay, M. Benderitter, and J. Voswinkel, "Newinsights for pelvic radiation disease treatment: multipotent stromal cell is a promisemainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy," World Journal of Stem Cells, vol. 5, no. 4, pp. 106-111, 2013.
4. J. Voswinkel, S. Francois, N. Gorin, and A. Chapel, "Gastrointestinal autoimmunity: Preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells," Immunologic Research, vol. 56, no. 2-3, pp. 241-248, 2013.
5. S. C. Schwarz and J. Schwarz, "Translation of stem cell therapy for neurological diseases," Translational Research, vol. 156, no. 3, pp. 155-160, 2010.
6. T. A. Wynn and T. R. Ramalingam, "Mechanisms of fibrosis: therapeutic translation for fibrotic disease," Nature Medicine, vol. 18, no. 7, pp. 1028-1040, 2012.
7. G. Gabbiani, "The biology of the myofibroblast," Kidney International, vol. 41, no. 3, pp. 530-532, 1992.
8. T. A.Wynn, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases," Journal of Clinical Investigation, vol. 117, no. 3, pp. 524-529, 2007.
9. Q. Yu and I. Stamenkovic, "Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- and promotes tumor invasion and angiogenesis," Genes and Development, vol. 14, no. 2, pp. 163-176, 2000.
10. M. H. Barcellos-Hoff and T.A.Dix, "Redox-mediated activation of latent transforming growth factor-1,"Molecular Endocrinology, vol. 10, no. 9, pp. 1077-1083, 1996.
11. R. M. Lyons, J. Keski-Oja, and H. L. Moses, "Proteolytic activation of latent transforming growth factor- from fibroblastconditionedmedium," Journal of Cell Biology, vol. 106, no. 5, pp. 1659-1665, 1988.
12. E. J. Ehrhart, P. Segarini, M. L.-S. Tsang, A. G. Carroll, and M. H. Barcellos-Hoff, "Latent transforming growth factor 1 activation in situ: quantitative and functional evidence after low-dose -irradiation," The FASEB Journal, vol. 11, no. 12, pp. 991-1002, 1997.
13. F. Verrecchia, M. Chu, and A. Mauviel, "Identification of Novel TGF-/Smad Gene Targets inDermal Fibroblasts using a Combined cDNA Microarray/Promoter Transactivation Approach," Journal of Biological Chemistry, vol. 276, no. 20, pp. 17058-17062, 2001.
14. S. N. Flier, H. Tanjore, E. G. Kokkotou, H. Sugimoto, M. Zeisberg, and R. Kalluri, "Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis," Journal of Biological Chemistry, vol. 285, no. 26, pp. 20202-20212, 2010.
15. E. M. Zeisberg, O. Tarnavski, M. Zeisberg et al., "Endothelialto-mesenchymal transition contributes to cardiac fibrosis," Nature Medicine, vol. 13, no. 8, pp. 952-961, 2007.
16. F. Rieder and C. Fiocchi, "Intestinal fibrosis in IBD-A dynamic, multifactorial process," Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 4, pp. 228-235, 2009.
17. S. Barrientos, O. Stojadinovic, M. S. Golinko, H. Brem, and M. Tomic-Canic, "Growth factors and cytokines in wound healing,"Wound Repair and Regeneration, vol. 16,no. 5, pp. 585-601, 2008.
18. J. G. Abreu, N. I. Ketpura, B. Reversade, and E. M. De Robertis, "Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-," Nature Cell Biology, vol. 4, no. 8, pp. 599-604, 2002.
19. M. R. Duncan, K. S. Frazier, S. Abramson et al., "Connective tissue growth factor mediates transforming growth factor -induced collagen synthesis: Downregulation by cAMP," FASEB Journal, vol. 13, no. 13, pp. 1774-1786, 1999.
20. B. S.Weston, N. A.Wahab, and R. M. Mason, "CTGF mediates TGF-induced fibronectin matrix deposition by upregulating active 51 integrin in human mesangial cells," Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 601-610, 2003.
21. E. H. Choi, N. Lee, H. J. Kim et al., "Schisandra fructus extract ameliorates doxorubicin-induce cytotoxicity in cardiomyocytes: altered gene expression for detoxification enzymes," Genes and Nutrition, vol. 2, no. 4, pp. 337-345, 2008.
22. J. R. Teerlink, J. M. Pfeffer, and M. A. Pfeffer, "Progressive ventricular remodeling in response to diffuse isoproterenolinduced myocardial necrosis in rats," Circulation Research, vol. 75, no. 1, pp. 105-113, 1994.
23. T. Nishikimi, K. Uchino, and E. D. Frohlich, "Effects of 1-Adrenergic blockade on intrarenal hemodynamics in heart failure rats," The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 262, no. 2, part 2, pp. R198-R203, 1992.
24. A. L. Cochrane,M.M. Kett, C. S. Samuel et al., "Renal structural and functional repair in a mouse model of reversal of ureteral obstruction," Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 3623-3630, 2005.
25. V. H. Urbieta-Caceres, R. Lavi, X.-Y. Zhu et al., "Early atherosclerosis aggravates the effect of renal artery stenosis on the swine kidney," The American Journal of Physiology, vol. 299, no. 1, pp. F135-F140, 2010.
26. L. O. Lerman, R. S. Schwartz, J. P. Grande, P. F. Sheedy II, and J. C. Romero, "Noninvasive evaluation of a novel swine model of renal artery stenosis," Journal of the American Society of Nephrology, vol. 10, no. 7, pp. 1455-1465, 1999.
27. I. Herrero-Fresneda, J. Torras, A. Vidal, N. Lloberas, J. M. Cruzado, and J. M. Grinyó, "Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy," Transplantation, vol. 79, no. 2, pp. 165-173, 2005.
28. R. Chaaya, C. Alfarano, C. Guilbeau-Frugier et al., "Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin," Nephrology Dialysis Transplantation, vol. 26, no. 2, pp. 489-498, 2011.
29. C. Fleck, D. Appenroth, P. Jonas et al., "Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats: influence of sex, strain, and surgical procedure," Experimental and Toxicologic Pathology, vol. 57, no. 3, pp. 195-205, 2006.
30. L. W. D. Weber, M. Boll, and A. Stampfl, "Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model," Critical Reviews in Toxicology, vol. 33, no. 2, pp. 105-136, 2003.
31. C. A. Claussen and E. C. Long, "Nucleic acid recognition by metal complexes of bleomycin," Chemical Reviews, vol. 99, no. 9, pp. 2797-2816, 1999.
32. B. B. Moore and C. M. Hogaboam, "Murine models of pulmonary fibrosis," The American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 294, no.2,pp. L152-L160, 2008.
33. B. J. R. Junor, J. D. Briggs, and M. A. Forwell, "Sclerosing peritonitis-the contribution of chlorhexidine in alcohol," Peritoneal Dialysis Bulletin, vol. 5, no. 2, pp. 101-104, 1985.
34. T. Yamamoto, S. Takagawa, I. Katayama et al., "Animalmodel of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma," Journal of InvestigativeDermatology, vol. 112, no. 4, pp. 456-462, 1999.
35. J. A. Horton, E. J. Chung, K. E. Hudak et al., "Inhibition of radiation-induced skin fibrosis with imatinib," International Journal of Radiation Biology, vol. 89, no. 3, pp. 162-170, 2013.
36. T. Peters, A. Sindrilaru, B.Hinz et al., "Wound-healing defect of CD18?/? mice due to a decrease in TGF-1 and myofibroblast differentiation," The EMBO Journal, vol. 24, no. 19, pp. 3400-3410, 2005.
37. R. J. Berry, G. Wiernik, T. J. S. Patterson, and J. W. Hopewell, "Excess late subcutaneous fibrosis after irradiation of pig skin, consequent upon the application of the NSD formula," British Journal of Radiology, vol. 47, no. 557, pp. 277-281, 1974.
38. N. Hazra and M. Gulliford, "Evaluating pancreatitis in primary care: a population-based cohort study," The British Journal of General Practice, vol. 64, no. 622, pp. e295-e301, 2014.
39. J. Merkord, L. Jonas, H. Weber, G. Kröning, H. Nizze, and G. Hennighausen, "Acute interstitial pancreatitis in rats induced by dibutyltin dichloride (DBTC): pathogenesis and natural course of lesions," Pancreas, vol. 15, no. 4, pp. 392-401, 1997.
40. C. Linard, E. Busson,V.Holler et al., "Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs," Stem Cells Translational Medicine, vol. 2, no. 11, pp. 916-927, 2013.
41. L. Song, Y. J. Yang, Q. T. Dong et al., "Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swinemyocardial infarction via activation of nitric oxide synthase," PLoS ONE, vol. 8, no. 5, Article ID e65702, 2013.
42. S. M.Gorji, A. A. K.Malekshah, M. B.Hashemi-Soteh, A. Rafiei, K. Parivar, and N. Aghdami, "Effect of mesenchymal stem cells on doxorubicin-induced fibrosis," Cell Journal, vol. 14, no. 2, pp. 142-151, 2012.
43. L. Li, Y. Zhang, Y. Li et al., "Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenolinduced global heart failure," Transplant International, vol. 21, no. 12, pp. 1181-1189, 2008.
44. C.Mias, O. Lairez, E. Trouche et al., "Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction," Stem Cells, vol. 27, no. 11, pp. 2734-2743, 2009.
45. S. Ishikane, H. Hosoda, K. Yamahara et al., "Allogeneic transplantation of fetal membrane-derived mesenchymal stem cell sheets increases neovascularization and improves cardiac function aftermyocardial infarction in rats," Transplantation, vol. 96, no. 8, pp. 697-706, 2013.
46. G. A. Nasir, S.Mohsin, M. Khan et al., "Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice," Journal of Translational Medicine, vol. 11, no. 1, article 78, 2013.
47. T. Li, Y. Yan, B. Wang et al., "Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis," Stem Cells and Development, vol. 22, no. 6, pp. 845-854, 2013.
48. V. Rabani, M. Shahsavani, M. Gharavi, A. Piryaei, Z. Azhdari, and H. Baharvand, "Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression," Cell Biology International, vol. 34, no. 6, pp. 601-605, 2010.
49. B. Fang, M. Shi, L. Liao, S. Yang, Y. Liu, and R. C. Zhao, "Systemic infusion of FLK1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice," Transplantation, vol. 78, no. 1, pp. 83-88, 2004.
50. G. Ali, S. Mohsin, M. Khan et al., "Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis," Journal of Translational Medicine, vol. 10, no. 1, article 75, 2012.
51. R. Pan, P. Wang, L. Xiang, and J. Shao, "Delta-like 1 serves as a new target and contributor to liver fibrosis down-regulated by mesenchymal stem cell transplantation," Journal of Biological Chemistry, vol. 286, no. 14, pp. 12340-12348, 2011.
52. D. Zhang, M. Jiang, and D. Miao, "Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver cirrhosis in mouse," PLoS ONE, vol. 6, no. 2,Article ID e16789, 2011.
53. Y.Wang, F. Lian, J. Li et al., "Adipose derivedmesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats," Journal of Translational Medicine, vol. 10, no. 1, article 133, 2012.
54. S. Oyagi, M. Hirose, M. Kojima et al., "Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats," Journal of Hepatology, vol. 44, no. 4, pp. 742-748, 2006.
55. M. T. Abdel Aziz, H. M. Atta, S. Mahfouz et al., "Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis," Clinical Biochemistry, vol. 40,no. 12, pp. 893-899, 2007.
56. Y. Chang, J. Liu, P. Lin et al., "Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis," Life Sciences, vol. 85, no. 13-14, pp. 517-525, 2009.
57. M. Hardjo, M. Miyazaki, M. Sakaguchi et al., "Suppression of carbon tetrachloride-induced liver fibrosis by transplantation of a clonal mesenchymal stem cell line derived from rat bone marrow," Cell Transplantation, vol. 18, no. 1, pp. 89-99, 2009.
58. H. Qiao, Y. Tong, H. Han et al., "A novel therapeutic regimen for hepatic fibrosis using the combination ofmesenchymal stem cells and baicalin," Pharmazie, vol. 66, no. 1, pp. 37-43, 2011.
59. P. Tsai, T. Fu, Y. A. Chen et al., "The therapeutic potential of human umbilical mesenchymal stem cells fromWharton's jelly in the treatment of rat liver fibrosis," Liver Transplantation, vol. 15, no. 5, pp. 484-495, 2009.
60. Z. M. Bai, X. D. Deng, J. D. Li et al., "Arterially transplanted mesenchymal stem cells in amouse reversible unilateral ureteral obstructionmodel: in vivo bioluminescence imaging and effects on renal fibrosis," Chinese Medical Journal, vol. 126, no. 10, pp. 1890-1894, 2013.
61. B. Ebrahimi, A. Eirin, Z. Li et al., "Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis," PLoS ONE, vol. 8, no. 7,Article ID e67474, 2013.
62. H. J. Wu, W. H. Yiu, R. X. Li et al., "Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis," PLoS One, vol. 9, no. 3,Article ID e90883, 2014.
63. M. Franquesa, E. Herrero, J. Torras et al., "Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model," Stem Cells and Development, vol. 21, no. 17, pp. 3125-3135, 2012.
64. C. Alfarano, C. Roubeix, R. Chaaya et al., "Intraparenchymal Injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporineimmunosuppressed rats," Cell Transplantation, vol. 21, no. 9, pp. 2009-2019, 2012.
65. P. Semedo, M. Correa-Costa, M. A. Cenedeze et al., "Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model," Stem Cells, vol. 27, no. 12, pp. 3063-3073, 2009.
66. H. Asanuma, B. A. Vanderbrink, M. T. Campbell et al., "Arterially delivered mesenchymal stem cells prevent obstructioninduced renal fibrosis," Journal of Surgical Research, vol. 168, no. 1, pp. e51-e59, 2011.
67. Y. Moodley, D. Atienza, U. Manuelpillai et al., "Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycininduced lung injury,"American Journal of Pathology, vol. 175, no. 1, pp. 303-313, 2009.
68. L. A. Ortiz, F. Gambelli, C. McBride et al., "Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8407-8411, 2003.
69. M. Choi, T. Ban, and T. Rhim, "Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell," Molecules and Cells, vol. 37, no. 2, pp. 133-139, 2014.
70. S. Lee, A. Jang, Y. Kim et al., "Modulation of cytokine and nitric oxide by mesenchymal stemcell transfer in lung injury/fibrosis," Respiratory Research, vol. 11, article 16, 2010.
71. F. Zhao, Y. F. Zhang, Y. G. Liu et al., "Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats," Transplantation Proceedings, vol. 40, no. 5, pp. 1700-1705, 2008.
72. A.Gazdhar,N.Susuri, K.Hostettler et al., "HGFexpressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic," PLoS ONE, vol. 8, no. 6, Article ID e65453, 2013.
73. T. Ueno, A. Nakashima, S. Doi et al., "Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-1 signaling," Kidney International, vol. 84, no. 2, pp. 297-307, 2013.
74. C. H. Zhou, M. L. Li, A. L. Qin et al., "Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton's jelly," Pancreas, vol. 42, no. 8, pp. 1291-1302, 2013.
75. Y. Wu, S. Huang, J. Enhe et al., "Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice," InternationalWound Journal, 2013.
76. J.A.Horton, K. E. Hudak, E. J. Chung et al., "Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation," Stem Cells, vol. 31, no. 10, pp. 2231-2241, 2013.
77. Y.Qi, D. Jiang, A. Sindrilaru et al., "TSG-6 Released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis inmurine full-thickness skin wounds," Journal of InvestigativeDermatology, vol. 134, no. 2,pp. 526-537, 2014.
78. P. Mok, C. Leong, and S. Cheong, "Cellular mechanisms of emerging applications of mesenchymal stem cells," Malaysian Journal of Pathology, vol. 35, no. 1, pp. 17-32, 2013.
79. N. G. Singer and A. I. Caplan, "Mesenchymal stem cells: Mechanisms of inflammation," Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 457-478, 2011.
80. A. Corcione, F. Benvenuto, E. Ferretti et al., "Humanmesenchymal stem cells modulate B-cell functions," Blood, vol. 107, no. 1, pp. 367-372, 2006.
81. A. Keating, "How do mesenchymal stromal cells suppress T cells?" Cell Stem Cell, vol. 2, no. 2, pp. 106-108, 2008.
82. F. Bifari, V. Lisi, E. Mimiola, A. Pasini, and M. Krampera, "Immune modulation by mesenchymal stem cells," Transfusion Medicine and Hemotherapy, vol. 35, no. 3, pp. 194-204, 2008.
83. P.A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, "Interactions between human mesenchymal stem cells and natural killer cells," Stem Cells, vol. 24, no. 1, pp. 74-85, 2006.
84. Y. Taniyama, R. Morishita, M. Aoki et al., "Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy," Hypertension, vol. 40, no. 1, pp. 47-53, 2002.
85. Y. T. Chen, C. K. Sun, Y. C. Lin et al., "Adipose-derived mesenchymal stem cell protects kidneys against ischemiareperfusion injury through suppressing oxidative stress and inflammatory reaction," Journal of Translational Medicine, vol. 9, article 51, 2011.
86. C. K. Sun, C. H. Yen, Y. C. Lin et al., "Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model," Journal of Translational Medicine, vol. 9, no. 1, article 118, 2011.
87. S. Francois, M. Mouiseddine, B. Allenet-Lepage et al., "Human mesenchymal stem cells provide protection against radiationinduced liver injury by antioxidative process, vasculature protection, hepatocyte differentiation, and trophic effects," BioMed Research International, vol. 2014, Article ID 151679, 14 pages, 2014.
88. K. Kemp, K. Hares, E. Mallam, K. J. Heesom, N. Scolding, and A. Wilkins, "Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival," Journal of Neurochemistry, vol. 114, no. 6, pp. 1569-1580, 2010.
89. T. Kinnaird, E. Stabile, M. S. Burnett et al., "Marrow-derived stromal cells express genes encoding a broad spectrumof arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms," Circulation Research, vol. 94, no. 5, pp. 678-685, 2004.
90. S. C.Hung, R. R. Pochampally, S. C. Chen, S. C.Hsu, and D. J. Prockop, "Angiogenic effects of humanmultipotent stromal cell conditionedmediumactivate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis," StemCells, vol. 25,no. 9, pp. 2363-2370, 2007.
91. J. Niu, A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy, "Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP),"The Journal of Biological Chemistry, vol. 283, no. 21, pp. 14542-14551, 2008.
92. T. Kinnaird, E. S. Burnett, M. Shou et al., "Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrinemechanisms," Circulation, vol. 109, no. 12, pp. 1543-1549, 2004.
93. J. Rehman, D. Traktuev, J. Li et al., "Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells," Circulation, vol. 109, no. 10, pp. 1292-1298, 2004.
94. C. Strup-Perrot, D.Mathé, C. Linard et al., "Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis," American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 287, no. 4, pp. G875-G885, 2004.
95. D.Reinhardt,H.H. Sigusch, J.Hene, S. C. Tyagi, R. Körfer, and H. R. Figulla, "Cardiac remodelling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP," Heart, vol. 88, no. 5, pp. 525-530, 2002.
96. D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans, "Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window," Cardiovascular Research, vol. 69, no. 3, pp. 604-613, 2006.
97. S. Cheng, A. S. Pollock, R. Mahimkar, J. L. Olson, and D. H. Lovett, "Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury," The FASEB Journal, vol. 20, no. 11, pp. 1898-1900, 2006.
98. T. Yaguchi, Y. Fukuda, M. Ishizaki, and N. Yamanaka, "Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis," Pathology International, vol. 48, no. 12, pp. 954-963, 1998.
99. C.Mias, E. Trouche,M. H. Seguelas et al., "Ex vivopretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney," Stem Cells, vol. 26, no. 7, pp. 1749-1757, 2008.
100. H. K. Yip, Y. C. Chang, C. G. Wallace et al., "Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury," Journal of Pineal Research, vol. 54, no. 2, pp. 207-221, 2013.
101. C. L. Visage, O. Gournay, N. Benguirat et al., "Mesenchymal stem cell delivery into rat infarctedmyocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection," Tissue Engineering A, vol. 18, no. 1-2, pp. 35-44, 2012.
102. C. Ceccaldi, R. Bushkalova, C. Alfarano et al., "Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment," Acta Biomaterialia, vol. 10, no. 2, pp. 901-911, 2014.
103. M.M. Lalu,L.McIntyre, C. Pugliese et al., "Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-Analysis of clinical trials," PLoS ONE, vol. 7, no. 10, Article ID e47559, 2012.
104. K. C. Rustad and G. C. Gurtner, "Mesenchymal stem cells home to sites of injury and inflammation," Advances in Wound Care, vol. 1, no. 4, pp. 147-152, 2012.
105. M. Mohamadnejad, K. Alimoghaddam, M. Mohyeddin-Bonab et al., "Phase 1 trial of autologous bone marrow mesenchymal stemcell transplantation in patients with decompensated liver cirrhosis," Archives of Iranian Medicine, vol. 10, no. 4, pp. 459-466, 2007.
106. P. Kharaziha, P. M. Hellström, B. Noorinayer et al., "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial," European Journal of Gastroenterology and Hepatology, vol. 21, no. 10, pp. 1199-1205, 2009.
107. Z. Zhang, H. Lin, M. Shi et al., "Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients," Journal of Gastroenterology andHepatology, vol. 27, supplement 2,pp. 112-120, 2012.
108. P. S. Kamath, R. H. Wiesner, M. Malinchoc et al., "A model to predict survival in patients with end-stage liver disease," Hepatology, vol. 33, no. 2, pp. 464-470, 2001.
109. J. E. Ware Jr. and C. D. Sherbourne, "The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection," Medical Care, vol. 30, no. 6, pp. 473-483, 1992.
110. M. E. J. Reinders, J. W. De Fijter, H. Roelofs et al., "Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation:Results of a phase I study," Stem Cells Translational Medicine, vol. 2, no. 2, pp. 107-111, 2013.
111. J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction," Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
112. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., "Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial," JAMA, vol. 308, no. 22, pp. 2369-2379, 2012.
113. S. Saito, G.Matsumiya, T. Sakaguchi et al., "Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist," Journal of Heart and Lung Transplantation, vol. 29, no. 6, pp. 672-679, 2010.
114. J. J. Lataillade, C. Doucet, E. Bey et al., "New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy," Regenerative Medicine, vol. 2, no. 5, pp. 785-794, 2007.
115. R. Rafii, M. M. Juarez, T. E. Albertson, and A. L. Chan, "A review of current and novel therapies for idiopathic pulmonary fibrosis," Journal ofThoracicDisease, vol. 5, no. 1,pp. 48-73, 2013.
116. A. Salazar-Montes, L. Ruiz-Corro, A. López-Reyes, E. Castrej ón-Gómez, and J. Armendáriz-Borunda, "Potent antioxidant role of Pirfenidone in experimental cirrhosis," European Journal of Pharmacology, vol. 595, no. 1-3, pp. 69-77, 2008.
117. S. N. Iyer, G. Gurujeyalakshmi, and S. N. Giri, "Effects of pirfenidone on transforming growth factor- gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis," Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 1, pp. 367-373, 1999.
118. S. Mirkovic, A. L. Seymour, A. Fenning et al., "Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats," British Journal of Pharmacology, vol. 135, no. 4, pp. 961-968, 2002.
119. K. Takakuta, A. Fujimori, T. Chikanishi et al., "Renoprotective properties of pirfenidone in subtotally nephrectomized rats," European Journal of Pharmacology, vol. 629, no. 1-3,pp. 118-124, 2010.
120. A. Di Sario, E. Bendia, G.Macarri et al., "The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen 1(I), TIMP-1 and MMP-2," Digestive and Liver Disease, vol. 36, no. 11, pp. 744-751, 2004.
121. N. L. Simone, B. P. Soule, L. Gerber et al., "Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study," Radiation Oncology, vol. 2, no. 1, article 19, 2007.
122. Pulmonary-Allergy Drugs Advisory Committee Complete Response on Pirfenidone, Food and Drug Administration Center for Drug Evaluation and Research, March 2010, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM206399.pdf.
123. C. Jiang, H. Huang, J. Liu, Y. Wang, Z. Lu, and Z. Xu, "Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-Analysis of randomized controlled trials," PLoS ONE, vol. 7, no. 10, Article ID e47024, 2012.
124. J. Rosenbloom, F. A.Mendoza, and S. A. Jimenez, "Strategies for anti-fibrotic therapies," Biochimica et BiophysicaActa:Molecular Basis of Disease, vol. 1832, no. 7, pp. 1088-1103, 2013.
125. M. A. Ngo, A. Muller, Y. Li et al., "Human mesenchymal stem cells express a myofibroblastic phenotype in vitro: comparison to human cardiac myofibroblasts," Molecular and Cellular Biochemistry, vol. 392, no. 1-2, pp. 187-204, 2014.
126. L. Yang, N. Chang, X. Liu et al., "Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis," The American Journal of Pathology, vol. 181, no. 1, pp. 85-97, 2012.
127. S. Chakraborty, P. Chopra, A. Hak, S. G. Dastidar, and A. Ray, "Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis," Expert Opinion on Investigational Drugs, vol. 22, no. 4, pp. 499-515, 2013.